

INDICATION


Qelbree is indicated for the treatment of ADHD in adults and pediatric patients 6 years and older.

IMPORTANT SAFETY INFORMATION

WARNING: SUICIDAL THOUGHTS AND BEHAVIORS

In clinical studies, higher rates of suicidal thoughts and behaviors were reported in patients with ADHD treated with Qelbree than in patients treated with placebo. Closely monitor all Qelbree-treated patients for clinical worsening and for emergence of suicidal thoughts and behaviors.

Please see full Important Safety Information on page 2.



Now covered across 75% of commercial lives



CVS Caremark:

Qelbree is Tier 2 on Preferred Brand Tier with no restrictions/ no steps

27.2 million lives covered in Preferred Tier

Express Scripts (ESI):

Qelbree is covered by ESI after the trial of any ADHD medication

27.3 million lives covered in ESI National Preferred Formulary



For additional information about the Qelbree Patient Savings and Support Program, call 1-855-725-7736, or visit Qelbree.com.

Learn more today.

Abbreviation: ADHD, attention-deficit/hyperactivity disorder.

*Terms and Conditions: Offer applies only to prescriptions (1) that are subject to a private insurance co-pay requirement, or (2) for which the patient has no insurance. Offer not valid for patients who are enrolled in a federal or state program that provides prescription benefits through retail or mail-order pharmacies, including Medicare Part D and Medicaid. Offer void where prohibited. Other restrictions apply. For full terms and conditions, please see the Qelbree Co-pay Card, or visit www.Qelbree.com.

Please see full Important Safety Information on page 2.



INDICATION

Qelbree® (viloxazine extended-release capsules) is indicated for the treatment of ADHD in adults and pediatric patients 6 years and older.

IMPORTANT SAFETY INFORMATION

WARNING: SUICIDAL THOUGHTS AND BEHAVIORS

In clinical studies, higher rates of suicidal thoughts and behaviors were reported in patients with ADHD treated with Qelbree than in patients treated with placebo. Closely monitor all Qelbree-treated patients for clinical worsening and for emergence of suicidal thoughts and behaviors.

CONTRAINDICATIONS

- Concomitant administration of a monoamine oxidase inhibitor (MAOI), or dosing within 14 days after discontinuing an MAOI, because of an increased risk of hypertensive crisis
- Concomitant administration of sensitive CYP1A2 substrates or CYP1A2 substrates with a narrow therapeutic range

WARNINGS & PRECAUTIONS

- *Suicidal thoughts and behaviors*: Closely monitor all Qelbree-treated patients for clinical worsening and emergence of suicidal thoughts and behaviors, especially during the initial few months of drug therapy, and at times of dosage changes
- *Heart rate, blood pressure increases*: Qelbree can cause an increase in diastolic blood pressure and heart rate. Assess these measures prior to starting therapy, following increases in dosage, and periodically during therapy
- *Activation of mania or hypomania*: Noradrenergic drugs may induce a manic or mixed episode in patients with bipolar disorder. Prior to initiating treatment with Qelbree, screen patients to determine if they are at risk for bipolar disorder. Screening should include a detailed psychiatric history, including a personal or family history of suicide, bipolar disorder, and depression
- *Somnolence and fatigue*: Patients should not perform activities requiring mental alertness, such as operating a motor vehicle or hazardous machinery, due to potential somnolence (including sedation or lethargy) and fatigue, until they know how they will be affected by Qelbree

ADVERSE REACTIONS

The most common adverse reactions ($\geq 5\%$ and at least twice the rate of placebo for any dose) in patients 6 to 17 years were somnolence, decreased appetite, fatigue, nausea, vomiting, insomnia, and irritability, and in adults, insomnia, headache, somnolence, fatigue, nausea, decreased appetite, dry mouth, and constipation.

PREGNANCY

There is a pregnancy exposure registry that monitors pregnancy outcomes in women exposed to Qelbree during pregnancy. Healthcare providers are encouraged to register patients by calling the National Pregnancy Registry for Psychiatric Medications at 1-866-961-2388 or by visiting www.womensmentalhealth.org/preg.

Please see full [Prescribing Information](#), including **Boxed Warning**.



Qelbree is a registered trademark of Supernus Pharmaceuticals, Inc.
©2023 Supernus Pharmaceuticals, Inc. All rights reserved. QBE.2023-0266